Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Phase 2 Terminated 15 enrolled Sesen Bio, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, effectiveness, and recommended dose of Proxinium in North American patients with Squamous Cell Head and Neck Cancer

Timeline

Start: 2006-01
Primary completion: 2007-10
Completion: 2007-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual in North America”

Publications

Huang M, Park J, Seo J, Ko S, Yang YH, Lee Y, Kim HJ, Lee BS, Lee YS, Ko BJ, Jung ST, Park D, Yoo TH, Kim CH. An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer. FASEB J. 2024 Jul 15;38(13):e23759. doi: 10.1096/fj.202301968R.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Proxinium	Protein / enzyme biologic	260 ug	Other
Subject	Proxinium	Protein / enzyme biologic	500 ug	Other
Subject	Proxinium	Protein / enzyme biologic	700 ug	Other